In the realm of pharmacy benefit management, the term “patent expiration” often triggers a shift in the landscape, paving the way for clinically equivalent alternatives of popular drugs to enter the market. This encourages competition, which leads to critical cost-saving opportunities across the industry.
We took a high-level look at the top 10 prescription drugs losing exclusivity this year, along with when generic options are expected to be available (if they’re not available already), and summarized that information for you. As you review plan performance and forecast for January 1, you may want to consider if the future availability of lower-cost options could benefit your (or your clients’) bottom line.
Download a summary of the top 10 drugs losing exclusivity here.
What Steps Should You Take to Keep Your Pharmacy Benefit on Track?
Look at the utilization of the therapies listed in this summary. Is there an opportunity for cost containment by transitioning members from the brand drug to a forthcoming generic alternative? When you use a tool like Xevant’s ScripLogic, you can automate this task and quickly identify opportunities to save.
Also, as we discussed in an earlier article, you can proactively monitor your member population and get alerts when members are newly diagnosed with conditions that are treated by these drugs. From there you can make an informed decision on which therapies the plan should prefer on the formulary based on utilization and cost trends.
The pharmacy landscape evolves every day. With the right analytics and reporting tools, it’s easier than ever to stay on track with your cost and health care goals.
How can automated analytics keep you ahead of the changing drug landscape? Ask us.